Clinical trial
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That…
NCT00127829 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00127829 |
|---|---|
| Title | Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic |
| Official title | A Phase I, Open-Label, Dose Escalation Study Evaluating High-Dose Gefitinib (IRESSA®) on Weekly and Twice Weekly Schedules in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic |
| Acronym | AGUS |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Drug |
| Interventions | Gefitinib |
| Enrollment | 66 |
| Start date | Jul 1, 2005 |
| Completion | Jan 1, 2008 |
| First posted | Aug 9, 2005 |
| Last update posted | Apr 23, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: